Page 8 - Sohini Das

From treatment to trend, slimming drug boom sparks misuse concerns

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

VW group targets 5% India passenger vehicle market share by decade-end

Automaker aims to double India market share with new models, alternate fuel push and potential entry into sub-4 metre SUV segment by 2030

Mercedes-Benz drives past West Asia war turmoil with Q1 India growth

Strong demand for top-end luxury cars and EVs helps the carmaker post 5% sequential growth despite volatility, currency pressure and rising import costs

IPM growth at 10.5% marks 5-qtr high on steady pricing, volume recovery

Indian pharma market's growth was led more by price increases that an uptick in consumption

Tesla lags new foreign entrants in India EV race despite global playbook

VinFast and BYD outpace the US EV giant with sharper pricing, faster localisation signals and wider networks, even as Tesla sticks to an import-led strategy

India needs to rethink IPO norms for biotech startups: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw urges IPO reforms, saying India's listing norms hinder biotech firms that need long R&D cycles before generating revenue

Biocon seeks to be the top global insulin player as rivals turn to GLP-1

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Tata Motors leads PV recovery post-GST cut, outpaces peers in H2FY26

Co says strong product mix, multi-powertrain strategy drive volume and market share gains

After GST-led surge, car sales growth likely to decelerate in FY27

High base effect, weak pentup demand, and West Asia conflict to temper momentum

India likely to stay insulated from Trump's tariff shock on patented drugs

US tariffs on patented drugs may have limited immediate impact on India, but industry flags uncertainty as policy ties relief to pricing and manufacturing shifts

India's bioeconomy to hit $300 bn by 2033 on innovation demand: Report

Report flags global patent cliff and rising R&D costs as catalysts, with India emerging as a cost-efficient hub backed by policy support, faster trials and expanding biotech ecosystem

MNCs, Indian drugmakers diverge to mutual gain: How win-win is it?

Novartis exits India's mass-market generics, signalling a deeper split between MNC innovation bets and domestic pharma scale

Diet, screen time drive decline in mental health among India's youth: Study

A global study finds India's young adults scoring far below older generations on mental health, with rising consumption of ultra-processed food and increasing screen exposure emerging as key risks

Affordability keeps ICE relevant as buyers warm to hybrids: Study

Hybrids emerge as the preferred bridge technology as most buyers stay price-conscious, favour lower EMIs and take a cautious view on full electrification

Sedemac targets global markets as ISG tech gains traction with Indian OEMs

Pune-based Sedemac is engaging global OEMs to export its proprietary ISG technology, even as TVS, Bajaj and Hero scale domestic deployment ahead of the firm's March 2026 IPO

Indian MSME drugmakers likely to focus on Brazil as next growth market

India-Brazil pharma meet highlights Brazil's growing role as a priority market for Indian MSME drugmakers, driven by rising exports, regulatory engagement and demand for specialty medicines

Free HPV vaccination may sharply cut India's cervical cancer burden

Public-health experts say India's free HPV vaccination for 14-year-old girls could significantly lower cervical cancer cases and deaths, but warn success hinges on strong screening and sustained execu

AI, trust and faster innovation bets to shape India's pharma future by 2047

At the IPA summit, pharma leaders said India's 2047 ambitions depend on embedding AI, strengthening trust and accelerating innovation, as speed and quality become the sector's defining advantages

Balkrishna Ind enters consumer tyre market; eyes ₹23K cr topline by FY30

Balkrishna Industries earmarks Rs 3,500 crore to enter India's consumer tyre market, targeting a 2.2x rise in revenue by FY30 under its Vision 2030 strategy.

Torrent Group forays into diagnostics with large national reference lab

Torrent Group has entered the diagnostics sector with a 100,000 sq ft national reference lab in Navi Mumbai, marking a long-term push into high-end, specialised testing amid industry consolidation